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Introduction {#sec1}
============

Natural products with 2,5-diketopiperazine (DKP) scaffolds are a large class of specialized metabolites with structural diversity and notable bioactivities ([@bib4]). The DKP rings confer structural stability and rigidity against proteolysis, making them attractive in pharmaceutical development ([@bib4]). From the biosynthetic point of view, the DKP ring is assembled *via* a traditional non-ribosomal peptide synthetase (NRPS) or a recently characterized cyclodipeptide synthase (CDPS) machinery ([@bib2]). Notably, diverse tailoring enzymes are often found to be clustered with CDPSs to perform further modification reactions on the DKP rings such as oxidation ([@bib8]; [@bib19]; [@bib21]), methylation ([@bib9], [@bib10]; [@bib16]; [@bib18]; [@bib22]), prenylation ([@bib26]), as well as cyclization ([@bib26]), generating complex DKP-containing compounds. Although relatively few tailoring enzymes co-occurring with CDPS clusters have been experimentally characterized, most of them exhibit broad substrate scopes ([@bib9], [@bib10]; [@bib16]; [@bib18]; [@bib24]; [@bib26]). The small sizes and substrate promiscuities of the CDPSs and their associated tailoring enzymes highlight the CDPS pathway enzymes as potential powerful tools for the generation of structurally unique DKP compounds by combinatorial biosynthetic approaches. The use of CDPSs as "biosynthetic hooks" is thus considered an effective strategy for identifying genes modifying 2,5-DKP rings to expand the chemical space of DKPs ([@bib3]; [@bib5]).

Methylation of *O*-, *C*-, *N*-, and *S*-centered nucleophiles are ubiquitous tailoring reactions during the biosynthesis of small molecules, which increases the lipophilicity and membrane permeability of small-molecule scaffolds, enhancing their membrane transport, oral bioavailability, absorption, and excretion ([@bib1]; [@bib17]). *N*-methylation is envisioned as a promising way to rationally improve key pharmacokinetic characteristics of cyclic peptides ([@bib6]). Although bioinformatics analyses indicate the presence of a large number of methyltransferases (MTs) genetically associated with CDPSs ([@bib23]), most of them remain unexplored. Up to now, only five MTs from CDPS-dependent pathways have been functionally characterized: *O*-methyltransferase Ndas_1149 from the nocazine pathway methylating phenolic hydroxyl groups of *cyclo* (L-Phe-L-Tyr) (cFY) (Δ^3^), cFY(Δ^3^, Δ^6^) and *cyclo* (L-Tyr-L-Tyr) (cYY) (Δ^3^, Δ^6^) ([@bib9]), *N*-methyltransferase Amir_4628 catalyzing two successive *N*-methylations at the cWW ring to generate Me~2~-cWW ([@bib10]), GutE/PcmE from guanitrypmycin pathway transferring a methyl group onto the guaninyl residue ([@bib18]; [@bib22]), and *C*-methyltransferase StspM1 mediating *C*3-methylation of indole ring and cyclization between the indole *C*2 of the Trp residue and the α-nitrogen ([@bib16]). These facts drive us to explore novel MTs from CDPS-dependent pathways for the generation of diverse DKP derivatives. We previously identified three homologous CDPS *loci* *dmt1-3* encoding drimentines (DMTs) ([Figure 1](#fig1){ref-type="fig"}, [@bib26]), which are a family of terpenylated diketopiperazine alkaloids with antibacterial, antifungal, and anthelmintic activities ([@bib7]; [@bib13]). The CDPS DmtBs synthesize *cyclo* (L-Trp-L-Xaa) (cWX) (X = Val, Pro, Leu, Ile or Ala), followed by prenylation and cyclization, which are, respectively, accomplished by the phytoene-synthase-like (PSL) prenyltransferase DmtCs and the membrane terpene cyclase DmtAs to afford DMTs ([@bib26]). Noticeably, three putative MT genes are located adjacent to the *dmt2* *locus* (from *Streptomyces* sp. NRRL F-5123) and the *dmt3* *locus* (from *S. aidingensis* CGMCC 4.5739), suggesting that these two clusters might encode more complicated methylated DMTs. In contrast, no putative MT gene is found around the *dmt1* *locus* from *S. youssoufiensis* OUC6819, although this strain is able to produce drimentine F (DMT F), which harbors *N*15-methyl group ([@bib7]). Herein, on one hand, we characterized the function of the *dmt2-* and *dmt3*-associated MT genes; on the other hand, we deciphered the *N*15-methylation step during the biosynthesis of DMT F; thereby, two *S*-adenosylmethionine (SAM)-dependent *N*-MTs (DmtMT2-1 and DmtMT1) with different regioselectivities were obtained. Their substrate spectra were probed, revealing that both of them exhibited considerable substrate promiscuities. Mixing and matching *dmtMT2-1* and *dmtMT1* with other DMT biosynthetic genes afforded unnatural methylated DMTs, providing novel effective CDPS-associated MTs for compound structural diversification.Figure 1Genetic Organization of the *dmt1-3loci* and Structures of Their Encoding Compounds(A) *dmt1-3loci* from *S. youssoufiensis* OUC6819, *Streptomyces* sp. NRRL F-5123, and *S. aidingensis* CGMCC 4.5739. PT, prenyltransferase; CDPS, cyclodipeptide synthase; TC, terpene cyclase; MT, methyltransferase.(B) Chemical structures of drimentines, pre-drimentines, and their methylated derivatives. Compounds **7**--**10** and **13**--**16** are generated in this study.

Results {#sec2}
=======

Function of the MT Genes Adjacent to the *dmtLoci* {#sec2.1}
--------------------------------------------------

As indicated in [Figure 1](#fig1){ref-type="fig"} and [Table S3](#mmc1){ref-type="supplementary-material"}, DmtMT2-1 shows 36.7% identity/49.8% similarity to MitM (AAD28459.1), which functions as an aziridine *N*-methyltransferase during the biosynthesis of mitomycin ([@bib25]); DmtMT2-2 shows 16.4% identity/25.3% similarity to UbiE (YP_026269.1), which catalyzes the carbon methylation reaction in the biosynthesis of ubiquinone and menaquinone ([@bib15]); DmtMT3 shows 24.2% identity/34.6% similarity to PrmC (AY600244.1) of *Chlamydia trachomatis* involving in methylation of the class 1 peptide chain release factors ([@bib20]).

To investigate the function of these MT genes during the biosynthesis of DMTs, we solubly expressed them in *E. coli* ([Figure S1](#mmc1){ref-type="supplementary-material"}) and tested their enzymatic activities *in vitro*. Given methylation may occur at different phases during DMTs biosynthesis, different substrates were subjected to assays based on the encoding products of *dmt2/3* ([@bib26])*.* HPLC analysis of the reactions showed: (1) DmtMT2-1 was able to recognize both DMT A (**3**)/C (**4**) ([Figure 2](#fig2){ref-type="fig"}Ai and iii) and pre-DMT A (**5**)/C (**6**) ([Figure 2](#fig2){ref-type="fig"}Bi and iii), generating compounds **7**--**10**, but could not recognize cWL or cWP ([Figure S2](#mmc1){ref-type="supplementary-material"}A), which indicated that a pyrroloindoline ring is necessary for the activity of DmtMT2-1; (2) neither DmtMT2-2 ([Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D) nor DmtMT3 ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F) recognized the tested substrates.Figure 2*In Vitro* Methyltransferase Activity of DmtMT2-1In the presence of SAM, DmtMT2-1 converted DMT A (**3**)/C (**4**) (A) and pre-DMT A (**5**)/C (**6**) (B) to *N*4-methyl-DMT A (**7**)/C (**8**) and *N*4-methyl-pre-DMTA (**9**)/C (**10**), respectively. The red-tinted peaks represent the methylated products.See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Data S1](#mmc1){ref-type="supplementary-material"}.

Subsequently, large volume (30 mL) of reactions followed by chemical isolation was performed, leading to identification of compounds **7**--**10**. High-resolution electrospray ionization mass spectrometry (HR-ESI-MS) analysis indicated the molecular formula of **7** as C~33~H~47~N~3~O~2~ (*m/z* \[M + H\]^+^ 518.3778, calcd 518.3747, [Data S1](#mmc1){ref-type="supplementary-material"}), **8** as C~32~H~43~N~3~O~2~ (*m/z* \[M + H\]^+^ 502.3434, calcd 502.3434, [Data S1](#mmc1){ref-type="supplementary-material"}), **9** as C~33~H~47~N~3~O~2~ (*m/z* \[M + H\]^+^ 518.3776, calcd 518.3747, [Data S1](#mmc1){ref-type="supplementary-material"}), and **10** as C~32~H~43~N~3~O~2~ (*m/z* \[M + H\]^+^ 502.3476, calcd 502.3434, [Data S1](#mmc1){ref-type="supplementary-material"}), which are 14 mass units bigger than that of DMT A (**3**), DMT C (**4**), pre-DMT A (**5**), and pre-DMT C (**6**), respectively ([@bib26]). Comparison of the ^1^H and ^13^C NMR data between **7** and **3** ([@bib26]) revealed that they share similar structure except the presence of an additional methyl group (δ~H~ 2.87, δ~C~ 33.2) in **7** ([Data S1](#mmc1){ref-type="supplementary-material"}). Based on HMBC correlation observed from the methyl proton H-36 (δ~H~ 2.87) to C3 (δ~C~ 83.6) and C5 (δ~C~ 150.6), we determined the methyl group is attached to the nitrogen of the dihydroindole system instead of the DKP ring ([Data S1](#mmc1){ref-type="supplementary-material"}). Thus, compound **7** was determined as *N*4-methyl-DMT A. Similarly, compounds **8**--**10** are similar to DMT C (**4**), pre-DMT A (**5**), and pre-DMT C (**6**), respectively, but carry an additional methyl group (δ~H~ 2.88, δ~C~ 33.5 for **8**, δ~H~ 2.91, δ~C~ 33.2 for **9**, and δ~H~ 2.92, δ~C~ 33.5 for **10**) attached to the nitrogen of dihydroindole ([Data S1](#mmc1){ref-type="supplementary-material"}). Thereby, **8**--**10** were characterized as *N*4-methyl derivatives of compounds **4**--**6**. The above results supported that DmtMT2-1 is responsible for the *N*4-methylation during DMTs biosynthesis, which may happen before or after cyclization. It was worth to mention that methylation occurs only at *N*15 in all the reported methylated DMTs (DMT F, H, and I). Thus, the *N4*-methyltransferase DmtMT2-1 would expand the diversity of DMTs compounds.

Probing the MT Gene Involved in *N*15-Methylation of DMT F {#sec2.2}
----------------------------------------------------------

Although no MT gene is found adjacent to *dmt1*, *S. youssoufiensis* OUC6819 is able to produce DMT F, which harbors a methyl group at *N*15 position. This fact indicates that the responding MT gene is located in another place of the genome. With comparative liquid chromatography-mass spectrometry (LC-MS) analysis of the fermentation products from the OUC6819 strains, a compound peak with molecular weight of 14 Daltons bigger than that of cWV (*m/z* \[M + H\]^+^ calcd 286.1556; [Figure S3](#mmc1){ref-type="supplementary-material"}B) was observed in *ΔdmtC1* (the prenyltransferase gene in charge of the assembly of farnesyl group onto cWV) ([Figure S3](#mmc1){ref-type="supplementary-material"}Aii) and the *dmtB1* overexpression strain ([Figure S3](#mmc1){ref-type="supplementary-material"}Aiii) but not in the wild-type strain ([Figure S3](#mmc1){ref-type="supplementary-material"}Ai). This phenotype led us to hypothesize that methylation may happen before the assembly of the terpene moiety. Therefore, Amir_4628, which conducts two successive *N*-methylations at the DKP ring ([@bib10]), was subjected to BLAST against the OUC6819 genome, revealing a homologous gene *6880MT* (renamed as *dmtMT1*; 33.5% identity/45.0% similarity to Amir_4628) at 0.56 Mb upstream of the *dmt1* *locus* ([Figure 1](#fig1){ref-type="fig"}, [Table S3](#mmc1){ref-type="supplementary-material"}).

To detect if *dmtMT1* is involved in the biosynthesis of DMT F, in-frame deletion was performed, generating *ΔdmtMT1* ([Figure S4](#mmc1){ref-type="supplementary-material"}). HPLC analysis revealed that the production of DMT F was completely abolished; conversely, DMT G was still produced in *ΔdmtMT1* albeit in small amount ([Figure 3](#fig3){ref-type="fig"}ii). Moreover, complementation of *ΔdmtMT1* restored the production of DMT F ([Figure 3](#fig3){ref-type="fig"}iii); overexpression of *dmtMT1* resulted in increased production of DMT F by about 2-fold ([Figure 3](#fig3){ref-type="fig"}iv). These results ambiguously demonstrated *dmtMT1* to be responsible for the *N*15-methylation of DMT F.Figure 3HPLC Analysis of the Fermentation Products from OUC6819 Strains(i) WT, wild-type strain; (ii) *ΔdmtMT1*; (iii) *ΔdmtMT1 + dmtMT1*, genetic complementation strain of *ΔdmtMT1*; (iv) *dmtMT1* OE, overexpression strain of *dmtMT1*.

Timing of the *N*15-Methylation during DMT F Biosynthesis {#sec2.3}
---------------------------------------------------------

To identify the exact timing of the methylation step, *in vitro* biochemical reactions were carried out using cWV, pre-DMT G (**11**), and DMT G (**1**) as substrates. As indicated in [Figure 4](#fig4){ref-type="fig"}, DmtMT1 was capable of recognizing cWV to give a new peak ([Figure 4](#fig4){ref-type="fig"}A) but could not accept pre-DMT G or DMT G ([Figure S5](#mmc1){ref-type="supplementary-material"}), supporting the methyl group is assembled right after the formation of cWV. Time course analysis showed that only a single methylation takes place, as indicated by the presence of the sole product with a molecular ion peak \[M + H\]^+^ at *m*/*z* 300.1726, which was 14 units bigger than that of cWV (*m/z* \[M + H\]^+^ calcd 286.1556) ([Figures 4](#fig4){ref-type="fig"}A and 4B).Figure 4*In Vitro* Methyltransferase Activity of DmtMT1(A) Time course experiment of the DmtMT1-catalyzed reaction using cWV as substrate. Chromatograms show the absorbance at 280 nm.(B) HR-ESI-MS^2^ fragmentation spectrum of Me-cWV (*m*/*z* 300.1726).(C) Schematic representation of DmtMT1-catalyzed reaction illustrated by using cWV as substrate.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

To clarify the position of the methylation, HR-ESI-MS^2^ analysis was conducted. As shown in [Figure 4](#fig4){ref-type="fig"}B, in addition to the characteristic fragmentation pattern of 2,5-DKP with neutral losses of 28 Da (-CO) and 45 Da (-HCONH~2~) ([@bib12]), successive neutral loss of 59 Da corresponding to a HCONHCH~3~ fragment could also be detected, suggesting that the methylation takes place at the DKP ring; the protonated substituent ion at *m*/*z* 130 indicated the presence of tryptophan ([@bib12]); the ions at *m/z* 169.0984, 183.1130 resulting from elimination of 3-methyl-1-H-indole and indole, respectively, combined with *m/z* 86.0964 from sequential losses of CO and Trp residue proved that the methyl group is attached to the α-nitrogen of Val in cWV, which was further confirmed by the HMBC correlation of Me-cWV (**12**) from the methyl proton H-20 (δ~H~ 2.82) to C12 (δ~C~ 166.0) and C14 (δ~C~ 66.6) ([Figure 4](#fig4){ref-type="fig"}C and [Data S1](#mmc2){ref-type="supplementary-material"}).

This fact means the PSL-family prenyltransferase DmtC1, which transfers farnesyl group onto cWV to generate pre-DMT G ([@bib26]), should be able to recognize Me-cWV as well. Thus, we incubated DmtC1 with Me-cWV (**12**) in the presence of farnesyl diphosphate (FPP), and a new compound (**13**) appeared as expected ([Figure S6](#mmc1){ref-type="supplementary-material"}), with a molecular ion peak \[M + H\]^+^ at *m*/*z* 504.3579, which was 14 units bigger than that of pre-DMT G ([Data S1](#mmc1){ref-type="supplementary-material"}). The ^1^H and ^13^C NMR spectra of **13** provided a dataset similar to that of pre-DMT G, with the chemical shift difference observed for a methyl group (δ~H~ 2.81, δ~C~ 32.7) ([Data S1](#mmc1){ref-type="supplementary-material"}). The absence of one-proton singlet at δ~H~ 7.92 in pre-DMT G indicated that the methyl group was attached to *N*15 as confirmed by the strong HMBC correlation from the methyl proton H-35 (δ~H~ 2.81) to C14 (δ~C~ 165.1) and C16 (δ~C~ 66.3) ([Data S1](#mmc1){ref-type="supplementary-material"}). Considering the biosynthetic assembly line of DMT G, we proposed that compound **13** is the biosynthetic precursor of DMT F, and thus it was named as pre-DMT F, which would be further cyclized by the terpene cyclase DmtA1 to afford DMT F.

Probing Substrate Promiscuity of DmtMT2-1 and DmtMT1 {#sec3}
====================================================

With the two methyltransferases (DmtMT2-1 and DmtMT1) in hand, we evaluated their potentials as tool enzymes to diversify structures of DMT compounds. For DmtMT2-1, another two substrates, DMT G (**1**) and pre-DMT G (**11**), were tested. As shown in [Figure 5](#fig5){ref-type="fig"}A, both of them were recognized by DmtMT2-1, transforming **1** into **14** and **11** into **15** as expected. All the products were isolated and their structures elucidated by HR-ESI-MS and NMR analyses ([Data S1](#mmc1){ref-type="supplementary-material"}). Finally, **14** (*m/z* \[M + H\]^+^ 504.3630, calcd 504.3590) and **15** (*m/z* \[M + H\]^+^ 504.3647, calcd 504.3590) were determined to be *N*4-methyl-DMT G and *N*4-methyl-pre-DMT G as indicated by the HMBC correlations from the methyl proton H-35 (δ~H~ 2.86 for **14** and δ~H~ 2.91 for **15**) to C3 (δ~C~ 83.6 for **14** and δ~C~ 84.2 for **15**) and C5 (δ~C~ 150.8 for **14** and δ~C~ 150.9 for **15**) ([Data S1](#mmc1){ref-type="supplementary-material"}).Figure 5Substrate Promiscuities of DmtMT2-1 and DmtMT1(A) HPLC traces of DmtMT2-1-catalyzed reactions using DMT G (**1**) and pre-DMT G (**11**) as substrates.(B) Histogram of the conversion rates of DmtMT1 regarding different cyclodipeptides. The relative production amounts are obtained by comparison with the respective substrate calculated using UV trace integrals. Error bars represent ±SD of three independent experiments. HPLC traces and HR-ESI-MS^2^ spectra of each reaction are shown in [Data S2](#mmc2){ref-type="supplementary-material"}.

To probe the substrate promiscuity of DmtMT1, a series of DKPs were tested. Delightedly, DmtMT1 exhibited broad substrate flexibility and was able to recognize a bunch of DKPs, including cWL, cWI, cWA, cWT, cWF, cWY, cWW, and noticeably *cyclo* (D-Trp-L-Val) (cDWV) and cYV as well (the nomenclature of a cyclodipeptide is indicated here by the one-letter code for the two L-configured amino acids) ([Figure 5](#fig5){ref-type="fig"}B and [Data S2](#mmc2){ref-type="supplementary-material"}). The responding methylated DKPs were identified by HR-ESI-MS^2^ analysis ([Data S2](#mmc2){ref-type="supplementary-material"}). Their fragmentation patterns were in agreement with that of Me-cWV ([Figure 4](#fig4){ref-type="fig"}B), supporting that each *N*-methylation regio-specifically occurs at the position derived from the second amino acid (from the biosynthetic point of view). Based on the relative catalytic efficiencies, we can clearly see DmtMT1 prefers cWXs with X being aliphatic over aromatic amino acids ([Figure 5](#fig5){ref-type="fig"}B). Delightedly, DmtMT1 was capable of transferring the methyl group onto cDWV and cYV, albeit at much lower efficiencies, implying it has certain flexibility toward the first amino acid as well.

The above results indicated that both DmtMT2-1 and DmtMT1 are *N*-methyltransferases with broad substrate promiscuity and stringent regiospecificity, which would potentially serve as efficient catalysts for structural diversification in drug development.

Generation of Unnatural DMTs by Using the Logic of Synthetic Biology {#sec4}
====================================================================

The availability of these two MTs drove us to further generate unnatural DMT analogs by using the logic of synthetic biology. Based on the biosynthetic machinery of DMTs, we introduced *dmtMT2-1* or/and *dmtMT1* into different cells, including DMTs producer *S. youssoufiensis* OUC6819, *S. coelicolor* M1146/*dmtB1C1* (accumulating pre-DMTs), and *S. coelicolor* M1146/*dmtA1B1C1* (producing DMTs) ([@bib26]).

As shown in [Figure 6](#fig6){ref-type="fig"}, expression of *dmtMT2-1* in *S. coelicolor* M1146/*dmtB1C1* led to the appearance of three small peaks, which were identified to be methylated pre-DMT compounds **10**, **15**, and **9**, respectively ([Figure 6](#fig6){ref-type="fig"}iii and iv). When *dmtMT2-1* was introduced into *S. youssoufiensis* OUC6819, in addition to **14**, another compound peak **16** showed up ([Figure 6](#fig6){ref-type="fig"}vi and vii). Considering the regioselectivity of *dmtMT2-1*, we speculated **16** might be *N*4-methyl-DMT F, which was confirmed by HR-ESI-MS ([Data S1](#mmc1){ref-type="supplementary-material"}) and NMR data with the presence of the methyl group (δ~H~ 2.85, δ~C~ 31.4), along with its strong HMBC correlations to C3 (δ~C~ 82.8) and C5 (δ~C~ 151.5) ([Data S1](#mmc1){ref-type="supplementary-material"}).Figure 6Combinatorial Expression of *dmtMT1* and/or *dmtMT2-1* with *dmt1* Genes

Expression of *dmtMT1* in *S. coelicolor* M1146/*dmtB1C1* led to decreased amount of **11** and simultaneous accumulation of pre-DMT F (**13**) ([Figure 6](#fig6){ref-type="fig"}viii and ix). When introducing *dmtMT1* into *S. coelicolor* M1146/*dmtA1B1C1*, DMT F (**2**) was accumulated as expected ([Figure 6](#fig6){ref-type="fig"}xi and xii). Unfortunately, no new product was observed after further introduction of *dmtMT2-1* into *S. coelicolor* M1146/*dmtB1C1* + *dmtMT1* ([Figure 6](#fig6){ref-type="fig"}xiii).

Discussion {#sec5}
==========

CDPSs are small enzymes that utilize two aminoacyl-tRNAs to catalyze the formation of a 2,5-DKP ring system ([@bib11]). To date, over 110 CDPSs have been functionally characterized and usually exhibit a certain degree of substrate promiscuity, making CDPSs intriguing members of Nature\'s biosynthetic repertoire ([@bib5]). The resulting cyclodipeptides are generally further modified by at least one tailoring enzyme adjacent to CDPS, including formation of C-C bond and C-O bond, and regioselective methylation and prenylation ([@bib3]). In this study, we identified and characterized two promiscuous *N*-methyltransferases and elucidated the methylation machinery during DMTs biosynthesis through *in vivo* and *in vitro* experiments, providing significant insights into generation of DKP derivatives by using synthetic biology approaches.

Although both DmtMT2-1 and DmtMT1 are involved in DMT biosynthesis, they act at different timings with different manners of function. As indicated in [Figure 7](#fig7){ref-type="fig"}, in OUC6819, the methyl group is assembled right after the formation of cWV instead of happening as the last step, and the following prenylation and cyclization steps occur in parallel, indicating both DmtC1 and DmtA1 display flexible substrate promiscuity as well, which should be exploited further. Conversely, as a novel dihydroindole *N*-methyltransferase, DmtMT2-1 from *Streptomyces* sp. NRRL F-5123 functions after indole *C*3-normal prenylation, recognizing pre-DMTs, DMTs, and *N*15-methyl-DMTs. Such big structural differences between their substrates are in accordance with the low similarity/identity (29.5%/17.4%) between DmtMT2-1 and DmtMT1. Notably, mixing and matching of *dmtMT2-1* and *dmtMT1* with other DMT biosynthetic genes leads to generation of "unnatural" natural products *N*4-methyl-DMT G (**14**), *N*4-methyl-pre-DMT G (**15**), and *N*4-methyl-DMT F (**16**).Figure 7Assembly Lines of Drimentines Occurring in *S. youssoufiensis* OUC6819 (highlighted in red rectangle box) and *S. coelicolor* M1146/*dmtB1C1*+*dmtMT2-1*

In microbes, the genes responsible for production of a specialized metabolite are mostly found in close proximity to another in dedicated biosynthetic gene clusters. However, *dmtMT1* is located at 0.56 Mb downstream of the *dmt1* locus. In comparison with its homolog Amir_4628, which doubly methylates DKPs constituting two identical aromatic amino acids ([@bib10]), DmtMT1 prefers cWX with X being aliphatic amino acids and strictly methylates nitrogen originating from the X residue. Noticeably, DmtMT1 displays remarkable substrate promiscuity. It allows the second amino acid to be Phe and Tyr and even admits the first amino acid to be D-configured Trp and Tyr, making DmtMT1 a very promising tool enzyme for compound diversification.

With the advent of next-generation sequencing, massive microbial genome sequence data have been uploaded to the public domain. Simple BLAST-based searches reveal large numbers of MTs associated with CDPSs in prokaryotic genomes. Hence, we constructed a sequence similarity network from selected MT sequences and assigned them to known MTs. As indicated in [Figure S7](#mmc1){ref-type="supplementary-material"}, three MT homologs (WP_055513754.1, WP_029387245.1, and WP_078513178.1) clustered with DmtMT2-1 are associated with a CDPS and a PSL-prenyltransferase, indicating that they might be involved in the biosynthesis of novel DMT-like compounds; noticeably, another four DmtMT2-1 homologs (StspM2/StflM2/5971M2/StalM2) are proposed to be involved in the *N*-methylation step during nocardioazine biosynthesis, but no *in vivo* nor *in vitro* results are provided ([@bib16]). Our results would enlighten deciphering of the methylation steps of nocardioazine-like natural products. Moreover, there are still several MTs that are not clustered with any known MTs, suggesting the untapped potentials of MTs as sources of new catalysts.

Apart from methyltransferases, we note that several other ORFs are in close proximity to CDPSs in cluster *dmt2/3*, such as the cyclodipeptide oxidases (CDOs), which have been reported to catalyze Cα-Cβ dehydrogenations on diverse cyclodipeptides ([@bib9]; [@bib14])*.* Thus, further experiments are required to completely characterize the functions of these proteins and gain a broader understanding of DMTs biosynthesis.

Limitations of the Study {#sec5.1}
------------------------

The molecular mechanism underlying the promiscuity of DmtMT1 and DmtMT2-1 has not been elucidated in the present study. Future crystallographic studies and systematic structure-guided mutagenesis would shed light on these issues.

Resource Availability {#sec5.2}
---------------------
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### Materials Availability {#sec5.2.2}
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### Data and Code Availability {#sec5.2.3}

The accession number for the *dmtMT1* reported in this paper is GenBank: MK894429 (<https://www.ncbi.nlm.nih.gov/nuccore/MK894429.1>). All relevant data supporting the findings of this study are available within the paper and its [Supplemental Information](#appsec1){ref-type="fn"} files. Additional data are provided upon reasonable request.

Methods {#sec6}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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